MERCK Kommanditgesellschaft auf Aktien Competitors

Abacus Health Products (OTCMKTS:ABAHF) and MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKKGY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Abacus Health Products and MERCK Kommanditgesellschaft auf Aktien's revenue, earnings per share and valuation.

Profitability

This table compares Abacus Health Products and MERCK Kommanditgesellschaft auf Aktien's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Abacus Health Products and MERCK Kommanditgesellschaft auf Aktien, as provided by MarketBeat.

Summary

MERCK Kommanditgesellschaft auf Aktien beats Abacus Health Products on 1 of the 1 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKKGY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Acreage and MERCK Kommanditgesellschaft auf Aktien's revenue, earnings per share and valuation.

Profitability

This table compares Acreage and MERCK Kommanditgesellschaft auf Aktien's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Acreage and MERCK Kommanditgesellschaft auf Aktien, as provided by MarketBeat.

Acreage presently has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Given Acreage's stronger consensus rating and higher possible upside, equities analysts clearly believe Acreage is more favorable than MERCK Kommanditgesellschaft auf Aktien.

Summary

Acreage beats MERCK Kommanditgesellschaft auf Aktien on 3 of the 3 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKKGY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Applied Biosciences and MERCK Kommanditgesellschaft auf Aktien's revenue, earnings per share and valuation.

Profitability

This table compares Applied Biosciences and MERCK Kommanditgesellschaft auf Aktien's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Applied Biosciences and MERCK Kommanditgesellschaft auf Aktien, as provided by MarketBeat.

Summary

MERCK Kommanditgesellschaft auf Aktien beats Applied Biosciences on 1 of the 1 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKKGY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Profitability

This table compares Ayr Strategies and MERCK Kommanditgesellschaft auf Aktien's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for Ayr Strategies and MERCK Kommanditgesellschaft auf Aktien, as provided by MarketBeat.

Ayr Strategies presently has a consensus price target of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' stronger consensus rating and higher possible upside, equities analysts clearly believe Ayr Strategies is more favorable than MERCK Kommanditgesellschaft auf Aktien.

Valuation and Earnings

This table compares Ayr Strategies and MERCK Kommanditgesellschaft auf Aktien's revenue, earnings per share and valuation.

Summary

Ayr Strategies beats MERCK Kommanditgesellschaft auf Aktien on 3 of the 3 factors compared between the two stocks.

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKKGY) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares MERCK Kommanditgesellschaft auf Aktien and Can B's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for MERCK Kommanditgesellschaft auf Aktien and Can B, as provided by MarketBeat.com.

Valuation & Earnings

This table compares MERCK Kommanditgesellschaft auf Aktien and Can B's top-line revenue, earnings per share (EPS) and valuation.

Summary

MERCK Kommanditgesellschaft auf Aktien beats Can B on 1 of the 1 factors compared between the two stocks.

MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKKGY) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Profitability

This table compares MERCK Kommanditgesellschaft auf Aktien and Cansortium's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for MERCK Kommanditgesellschaft auf Aktien and Cansortium, as provided by MarketBeat.com.

Cansortium has a consensus target price of $1.20, indicating a potential upside of 39.67%. Given Cansortium's stronger consensus rating and higher possible upside, analysts clearly believe Cansortium is more favorable than MERCK Kommanditgesellschaft auf Aktien.

Valuation & Earnings

This table compares MERCK Kommanditgesellschaft auf Aktien and Cansortium's top-line revenue, earnings per share (EPS) and valuation.

Summary

Cansortium beats MERCK Kommanditgesellschaft auf Aktien on 2 of the 2 factors compared between the two stocks.